全文获取类型
收费全文 | 1357808篇 |
免费 | 103199篇 |
国内免费 | 6972篇 |
专业分类
耳鼻咽喉 | 18892篇 |
儿科学 | 43968篇 |
妇产科学 | 38735篇 |
基础医学 | 193936篇 |
口腔科学 | 36697篇 |
临床医学 | 120022篇 |
内科学 | 260337篇 |
皮肤病学 | 27375篇 |
神经病学 | 102088篇 |
特种医学 | 52582篇 |
外国民族医学 | 382篇 |
外科学 | 203061篇 |
综合类 | 45737篇 |
现状与发展 | 24篇 |
一般理论 | 304篇 |
预防医学 | 100983篇 |
眼科学 | 31027篇 |
药学 | 108051篇 |
157篇 | |
中国医学 | 9781篇 |
肿瘤学 | 73840篇 |
出版年
2021年 | 11551篇 |
2018年 | 14302篇 |
2017年 | 11744篇 |
2016年 | 12532篇 |
2015年 | 15432篇 |
2014年 | 20836篇 |
2013年 | 29726篇 |
2012年 | 41127篇 |
2011年 | 43897篇 |
2010年 | 27388篇 |
2009年 | 25280篇 |
2008年 | 40777篇 |
2007年 | 43524篇 |
2006年 | 43493篇 |
2005年 | 41884篇 |
2004年 | 39258篇 |
2003年 | 37922篇 |
2002年 | 36941篇 |
2001年 | 59645篇 |
2000年 | 60792篇 |
1999年 | 51506篇 |
1998年 | 14634篇 |
1997年 | 13212篇 |
1996年 | 13406篇 |
1995年 | 12616篇 |
1994年 | 12034篇 |
1993年 | 11019篇 |
1992年 | 41091篇 |
1991年 | 40464篇 |
1990年 | 39981篇 |
1989年 | 38783篇 |
1988年 | 36176篇 |
1987年 | 35398篇 |
1986年 | 33761篇 |
1985年 | 32166篇 |
1984年 | 23940篇 |
1983年 | 20822篇 |
1982年 | 12386篇 |
1979年 | 22639篇 |
1978年 | 15879篇 |
1977年 | 13735篇 |
1976年 | 12970篇 |
1975年 | 14202篇 |
1974年 | 16685篇 |
1973年 | 16079篇 |
1972年 | 15324篇 |
1971年 | 14235篇 |
1970年 | 13214篇 |
1969年 | 12734篇 |
1968年 | 11978篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
2.
3.
本文通过对《中医基本名词术语中英对照国际标准》和《WHO西太平洋地区传统医学名词术语国际标准》舌诊术语进行比较,分析两部标准中舌诊术语英译的优缺点,提出更适宜优先选择作为中医舌诊术语英译标准的方案,以期为中医名词术语标准化工作提供参考。 相似文献
4.
宫腔积液指宫腔内液体积存(积水、积血或积脓),是绝经后女性常见体征之一,常于超声检查时发现。持续宫腔积液患者,需宫腔镜检查寻找病因。本文报道1例以宫腔积液为首发症状,经宫腔镜检查确诊为胃型宫颈腺癌的患者。通过病例回顾并文献复习,以期为更多绝经后宫腔积液及宫颈病变的诊断提供参考,避免漏诊及误诊。1病例资料患者67岁,女,主因"绝经18年,不规则阴道出血2月"于2020年5月就诊于首都医科大学附属北京妇产医院妇科微创中心。 相似文献
5.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
6.
7.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
8.
9.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
10.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献